If a medication is available in the US but not in your country, read When conventional access fails.
Specialty drug access in Egypt: the named-patient pathway
From first request to drug delivery, a transparent walkthrough of every step.
Last reviewed 2026-05-01 by Reserve Meds clinical & regulatory team. Egypt patients access specialty drugs through a specific regulatory framework documented here.
Why Egypt patients face an access gap in the first place
Egypt has the largest patient population in Reserve Meds' MENA priority countries and a substantial private-sector specialty hospital ecosystem. The Egyptian Drug Authority (EDA) — established in 2019 as an independent regulator separated from the Ministry of Health — handles drug registration and named-patient import. Egypt's high disease burden in oncology (driven historically by hepatitis C-related hepatocellular carcinoma, though HCV prevalence has dropped substantially since the 2014 nationwide treatment campaign) and increasing specialty drug demand have expanded the named-patient pathway's use over the past five years.
Three patterns of access gap apply across Egypt:
- Registered but not stocked. A drug is on the EDA list but a particular hospital pharmacy does not have it on hand.
- Registered for a different indication. A drug is registered for one indication but the physician is prescribing it for another FDA-approved use that is not locally registered.
- Not registered locally at all. A drug is FDA-approved in the United States but the manufacturer has not pursued local registration, often because the patient population is small.
The EDA (Egyptian Drug Authority) named-patient framework
EDA's named-patient framework allows a licensed Egyptian physician to request import of an unregistered medicine for a specific patient. The application is filed through the dispensing pharmacy — typically a private-sector specialty hospital with import infrastructure. EDA reviews clinical justification, prior treatment history, evidence of FDA or EMA approval, manufacturer authorization, and chain-of-custody documentation. The 2019 EDA Law (Law No. 151 of 2019) consolidated regulatory authority and brought formalization to the framework.
The application includes:
- Clinical justification letter (diagnosis, severity, prior therapies, why this specific drug)
- Treating physician's local medical license verification
- Patient identifier (anonymized reference preferred)
- Product details: brand name, generic name, manufacturer, strength, quantity
- Destination dispensing facility license
- Chain-of-custody plan from US source to dispensing pharmacy
Approval timelines for routine cases are typically 20-35 business days. Complex cases (rare drug, novel mechanism, off-label use) can extend to 8-14 weeks.
Egypt's private specialty hospital network
The hospitals that handle named-patient imports as established workflow include: Cleopatra Hospital, As-Salam International Hospital, El-Shorouk Hospital, Cairo Specialized Hospital, Children's Cancer Hospital Egypt 57357 (CCHE 57357), El-Demerdash Cairo University Hospital. These institutions have import pharmacy infrastructure and physicians experienced with framework applications. If your treating physician is at a smaller institution without import infrastructure, we can help coordinate with one of these centers.
Real costs: what Egypt patients actually pay
Costs vary widely by drug. For context, a 30-day supply of a major specialty oral oncology drug (for example, a kinase inhibitor or BTK inhibitor) typically falls in a USD 5,500-10,500 monthly range for the drug itself, plus international logistics (EGP-equivalent of USD 400-1,500 depending on cold chain), plus regulatory documentation handling fees, plus our concierge fee.
For a CAR-T or gene therapy with a list price of USD 400,000-2,000,000, the cost structure changes substantially: the drug dominates everything else. Reserve Meds' role shifts from cost optimization to logistical and regulatory orchestration.
The waitlist form generates an indicative range first, then a transparent firm quote with each line item separated. Nothing is bundled or hidden.
The patient experience: what your family actually does
From the family side, the process looks like this:
- Your physician decides this drug is the right next step. That is a clinical decision and stays with them.
- Your physician (or the hospital's pharmacy team) reaches out to Reserve Meds, or the patient submits the waitlist request and we connect with the physician.
- We confirm eligibility within 24-48 hours and send a documentation kit to your physician.
- Your physician fills out the named-patient application and submits it to EDA.
- While the application processes, Reserve Meds aligns the US-side sourcing and shipment plan.
- Approval comes through. We ship cold-chain (or ambient, depending on the drug). Your hospital pharmacy receives the medicine.
- Your physician initiates therapy.
Common Egypt-specific questions
How does cash-pay work in Egypt given currency volatility?
Egypt has experienced significant EGP/USD volatility in recent years. Reserve Meds quotes patients in USD and accepts USD wire transfers; the patient or their family arranges USD via their banking channel. Some Egyptian families coordinate USD funds via family members in GCC, US, UK, or Europe. We do not handle currency conversion or local-currency banking. The transparent USD quote means patients know exactly what they need to wire regardless of local exchange rate movements.
What if the drug is a controlled substance?
Reserve Meds does not handle controlled substances (DEA Schedule I-V). Controlled-substance imports require separate regulatory coordination beyond the named-patient framework; we refer those cases to specialists.
Can I receive the drug at home or do I need a hospital?
The dispensing facility must be locally licensed. For oral medicines, a hospital outpatient pharmacy or specialized import pharmacy can dispense. For infusion products, the medicine ships to the infusion center where you will receive it. Direct-to-home delivery without a licensed dispensing facility in the chain is not the model.
What about pediatric patients?
The framework applies the same way for pediatric patients. The clinical justification letter typically includes weight-adjusted dosing and pediatric-specific monitoring requirements. The pediatric oncology and rare disease centers in Egypt handle named-patient imports routinely.
Regional context
Egypt's EDA framework is functional but typically slower than GCC and Indian frameworks (20-35 business days routine). The private-sector specialty hospital network — particularly the cluster of private oncology centers in Cairo and Alexandria — handles named-patient cases routinely. Some Egyptian patients with means coordinate care between Egyptian physicians and GCC tertiary centers; Reserve Meds can support both pathways.
Where Reserve Meds fits
Reserve Meds is a US-based concierge coordinator. We do not replace your physician, do not replace EDA, do not replace your dispensing pharmacy. What we do is orchestrate the US-side sourcing, the regulatory documentation kit your physician needs, the international logistics, and a single named coordinator throughout your case.
For specialty oncology, rare disease, immunology, neurology, and other specialty therapies, this orchestration is the difference between an unpredictable ad-hoc process and a predictable, documented cycle.
This guide is informational, not medical or legal advice. The named-patient framework requires a licensed Egypt physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.
Drug-access guides for Egypt
Each guide below is a named-patient access pathway for that specific drug in Egypt, with real timelines, costs, and the documentation your physician needs. These are coordinated by Reserve Meds for cross-border procurement.